CareDx (CDNA) vs Veracyte (VCYT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
CareDx (CDNA) has outperformed Veracyte (VCYT) over the past year, gaining 329.7% versus a gain of 24.7%. Over five years, VCYT leads with a -4.4% price change compared with -11.2% for CDNA. Veracyte is the larger company by market cap ($3.47 billion vs $3.26 billion), about 1.1 times the size.
On valuation, Veracyte trades at a lower forward P/E (22.1x vs 48.9x for CareDx). Veracyte converts more of its revenue into profit, with a net margin of 12.8% versus -5.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CDNA | VCYT |
|---|---|---|
| Share price | $63.04 | $43.16 |
| Market cap | $3.26B | $3.47B |
| 1-day change | -1.18% | -3.34% |
| YTD return | +234.61% | +2.52% |
| 1-year return | +329.72% | +24.70% |
| 5-year return | -11.21% | -4.43% |
| P/E ratio (TTM) | 30.31 | 30.83 |
| Forward P/E | 48.87 | 22.13 |
| EPS (TTM) | $2.08 | $1.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $379.81M | $517.14M |
| Revenue growth (YoY) | +13.79% | +16.01% |
| Net income (latest FY) | $-21.35M | $66.35M |
| Gross margin | — | 70.10% |
| Operating margin | -8.10% | 11.17% |
| Net margin | -5.62% | 12.83% |
| 52-week high | $72.51 | $60.91 |
| 52-week low | $13.95 | $29.46 |
| Distance from 52-week high | -13.06% | -29.14% |
| Analyst consensus | buy | buy |
| Avg. price target upside | -6.68% | +35.36% |
| Average volume | 1.28M | 1.35M |
| Shares outstanding | 51.73M | 80.39M |
| Employees | 761 | 755 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CDNA has outperformed VCYT by 305.0 percentage points over the past year.
- Veracyte is more profitable, keeping 12.8 cents of every revenue dollar as net income versus -5.6 cents for CareDx.
About CareDx
CDNA stock →CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally.
Health Care · Medical Specialities · 761 employees
About Veracyte
VCYT stock →Veracyte, Inc. operates as a diagnostics company in the United States and internationally.
Health Care · Medical Specialities · 755 employees
CDNA vs VCYT FAQ
Which is bigger, CareDx or Veracyte?
Veracyte (VCYT) is larger, with a market capitalization of $3.47B compared with $3.26B for CareDx (CDNA).
Which stock has performed better over the past year, CDNA or VCYT?
CDNA returned +329.72% over the past 12 months, compared with +24.70% for VCYT (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, CDNA or VCYT?
CDNA has the lower trailing P/E at 30.3, versus 30.8 for VCYT. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are CareDx and Veracyte in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.